#United States #Columbus #LUNGevity #Rising Tide #Bobak Parang

Groundbreaking Research in Lung Cancer Treatment

On October 28, 2026, Dr. Bobak Parang from The Ohio State University Comprehensive Cancer Center was announced as the recipient of the Rising Tide/LUNGevity Award, recognizing his efforts in combating drug resistance in EGFR-positive non-small cell lung cancer (NSCLC). This award comes with a funding of $620,000, aimed at supporting a revolutionary clinical trial designed to advance treatment options for lung cancer patients, particularly those whose tumors are driven by mutations in the EGFR gene.

The Challenge of Drug Resistance

Approximately 15% of NSCLC patients in the United States, along with 35% of individuals from East Asia, possess tumors containing the EGFR mutation. Although targeted treatments such as tyrosine kinase inhibitors (TKIs) are initially effective in halting tumor growth, resistance frequently develops over time. This phenomenon is primarily due to the emergence of drug-tolerant persister (DTP) cells, which adapt to evade treatment. These DTP cells pose a significant challenge in the management of EGFR-positive lung cancer, necessitating innovative strategies to prolong the efficacy of existing therapies.

The Clinical Trial

Dr. Parang's ambitious research project aims to combine osimertinib, a well-established TKI, with a second FDA-approved drug, alectinib. Alectinib not only targets ALK-positive NSCLC but also inhibits the FER gene, which is known to become active in DTP cells. This dual approach is hypothesized to effectively eliminate DTP cells, thus potentially preventing the resistance that commonly arises with osimertinib treatment. If successful, this clinical trial could transform treatment regimens, offering a new hope for patients afflicted with stage IV EGFR-positive NSCLC, potentially turning what is often a fatal diagnosis into a manageable, chronic condition.

Collaborative Efforts and Future Aspirations

The collaboration between LUNGevity and the Rising Tide Foundation for Clinical Cancer Research exemplifies a strategic investment in addressing the challenges posed by drug resistance in lung cancer treatment. Dr. Karolina Werynska, the Senior Scientific Program Manager at RTFCCR, emphasized the urgent need for solutions to support EGFR-positive lung cancer patients. “Patients need a means to stop drug resistance, allowing them to stay on treatment longer. The urgency of this research cannot be overstated,” she stated.

In echoing these sentiments, Upal Basu Roy, Executive Director of LUNGevity Research, recognized the difficulty many researchers face in securing funding for early-phase clinical trials, highlighting the critical nature of this project. This partnership not only seeks to bring new therapeutic options to patients but also fosters a deeper understanding of lung cancer biology, offering hope to countless individuals and their families battling this deadly disease.

Understanding Lung Cancer Statistics

Lung cancer remains a significant public health issue, with about 1 in 19 Americans likely to be diagnosed during their lifetime. In 2026 alone, over 229,000 new cases are expected in the U.S., with a diagnosis occurring every 2.3 minutes. Alarmingly, the disease claims more lives than the next two most lethal cancers, colorectal and pancreatic cancer, combined. Moreover, approximately 65% of new lung cancer diagnoses occur in individuals without a history of tobacco exposure. However, if lung cancer is detected before it spreads, the five-year survival rate can improve significantly.

LUNGevity Foundation, the leading nonprofit organization funding lung cancer research in the U.S., is committed to progressing research in early detection and treatments while advocating for better patient support systems. By merging patient experiences with cutting-edge research, LUNGevity aims to ensure that advancements resonate with the actual needs of individuals diagnosed with lung cancer and ultimately works towards a future where lung cancer deaths are significantly reduced.

Conclusion

Dr. Parang’s recognition by the Rising Tide/LUNGevity Foundation stands as a testament to the vital need for continual research and innovation in the fight against lung cancer. With promising trials on the horizon, patients suffering from EGFR-positive NSCLC may soon have access to groundbreaking treatments that hold the potential to drastically alter their prognosis. The fight against drug resistance is not only crucial in enhancing treatment efficacy but is also pivotal in transforming lung cancer from a life-threatening illness into a manageable condition, thereby improving the quality of life for countless patients.